<DOC>
	<DOCNO>NCT01248897</DOCNO>
	<brief_summary>The purpose study understand information 3 specific biomarkers provide guidance physician treatment erbB2 positive breast cancer patient .</brief_summary>
	<brief_title>Study Biomarker Profiles Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib</brief_title>
	<detailed_description />
	<mesh_term>Lapatinib</mesh_term>
	<criteria>1 . HER2positive ( define either ( ) IHC3+ ( b ) FISH+ local lab ) recurrent / metastatic breast cancer patient receive treatment lapatinibbased regimen . These either new , current complete case follow setting : treat accord physician 's clinical judgement routine practice ; treat clinical trial know allocation lapatinibbased regimen ; treat via lapatinib expand access name patient program . These regimen contain lapatinib antiHER2 agent . 2 . Exposed &lt; 2 line trastuzumabbased regimen metastatic set prior start lapatinibbased regimen . These regimen contain trastuzumab antiHER2 agent . 3 . Patients historical tumor biopsy specimen available primary breast cancer diagnosis . If available , least specimen available anytime period patient start antiHER2 therapy . 4 . Willing give write informed consent release tumor biopsy specimen correspond clinical data . If consent could waive accord institutional practice ( eg . patient already decease , patient previously provide blanket consent institution utilize tissue/data research purpose ) , accept appropriate support documentation . 1 . Patients expose experimental antiHER2 therapy eg . pertuzumab , trastuzumabDM , neratinib , ertumaxomab , AV412 , BIBW2992 , CUDC101 , antiHER2 vaccine . 2 . Other primary lesion breast origin .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>